IS6467A - Díhýdró-1,3,5-tríasín amínafleiður og notkun þeirra í meðferð - Google Patents

Díhýdró-1,3,5-tríasín amínafleiður og notkun þeirra í meðferð

Info

Publication number
IS6467A
IS6467A IS6467A IS6467A IS6467A IS 6467 A IS6467 A IS 6467A IS 6467 A IS6467 A IS 6467A IS 6467 A IS6467 A IS 6467A IS 6467 A IS6467 A IS 6467A
Authority
IS
Iceland
Prior art keywords
dihydro
therapy
amine derivatives
triazine amine
triazine
Prior art date
Application number
IS6467A
Other languages
English (en)
Inventor
Moinet Gérard
Cravo Daniel
Doare Liliane
Kergoat Micheline
Mesangeau Didier
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8846333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6467(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipha filed Critical Lipha
Publication of IS6467A publication Critical patent/IS6467A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/72—Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS6467A 2000-01-26 2002-07-11 Díhýdró-1,3,5-tríasín amínafleiður og notkun þeirra í meðferð IS6467A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0000996A FR2804113B1 (fr) 2000-01-26 2000-01-26 Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
PCT/FR2001/000241 WO2001055122A1 (fr) 2000-01-26 2001-01-25 Derives amines de dihydro-1,3,5-triazine et leurs applications en therapeutique

Publications (1)

Publication Number Publication Date
IS6467A true IS6467A (is) 2002-07-11

Family

ID=8846333

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6467A IS6467A (is) 2000-01-26 2002-07-11 Díhýdró-1,3,5-tríasín amínafleiður og notkun þeirra í meðferð

Country Status (36)

Country Link
US (4) US7034021B2 (is)
EP (1) EP1250328B2 (is)
JP (1) JP4926357B2 (is)
KR (1) KR100722438B1 (is)
CN (1) CN1195743C (is)
AP (1) AP2002002578A0 (is)
AR (1) AR027293A1 (is)
AT (1) ATE332294T1 (is)
AU (1) AU782307B2 (is)
BG (1) BG106933A (is)
BR (1) BRPI0107815B8 (is)
CA (1) CA2397636C (is)
CY (1) CY1105344T1 (is)
CZ (1) CZ303445B6 (is)
DE (1) DE60121294T3 (is)
DK (1) DK1250328T4 (is)
EA (1) EA005378B1 (is)
EE (1) EE05003B1 (is)
ES (1) ES2267715T5 (is)
FR (1) FR2804113B1 (is)
HR (1) HRP20020625A2 (is)
HU (1) HU230790B1 (is)
IL (1) IL150530A0 (is)
IS (1) IS6467A (is)
MA (1) MA25650A1 (is)
MX (1) MXPA02007232A (is)
NO (1) NO20023532L (is)
OA (1) OA12165A (is)
PL (1) PL205345B1 (is)
PT (1) PT1250328E (is)
SI (1) SI1250328T2 (is)
SK (1) SK287647B6 (is)
TN (1) TNSN01012A1 (is)
WO (1) WO2001055122A1 (is)
YU (1) YU55602A (is)
ZA (1) ZA200205314B (is)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
CA2510468C (en) 2002-12-17 2011-01-04 Hamari Chemicals, Ltd. Novel 2,4-diamino-1,3,5-triazine derivative
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
ATE489370T1 (de) * 2005-06-14 2010-12-15 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896161B1 (fr) * 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896158B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
DE102007054416A1 (de) 2007-11-13 2009-05-14 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind
DE102008007314A1 (de) * 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
WO2009143041A1 (en) 2008-05-20 2009-11-26 Merck & Co., Inc. Efficient production of heterologous proteins using mannosyl transferase inhibitors
KR101618198B1 (ko) * 2008-05-23 2016-05-04 뽁셀 에스아에스 3,6-디히드로-1,3,5-트리아진 유도체의 제조방법
US20110207926A1 (en) * 2008-08-25 2011-08-25 Hamari Chemicals, Ltd. Novel dihydrotriazine derivative
TW201033182A (en) * 2008-12-12 2010-09-16 Poxel Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
US8592370B2 (en) * 2008-12-12 2013-11-26 Poxel S.A.S. Combination of insulin with triazine derivatives
WO2010103040A1 (en) 2009-03-10 2010-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) 5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension
JP5536869B2 (ja) 2009-03-26 2014-07-02 ポクセル・エスアーエス 優先晶出法を利用したジヒドロ−１，３，５トリアジンラセミ体のエナンチオマー分離のための方法
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948028B1 (fr) 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
WO2011154496A1 (en) 2010-06-09 2011-12-15 Poxel Treatment of type 1 diabetes
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
US8742103B2 (en) * 2010-12-01 2014-06-03 Poxel Separation of triazine derivatives enantiomers using tartaric acid
RU2658819C2 (ru) * 2016-05-26 2018-06-25 федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный технический университет" Применение гетероциклических гидразонов в качестве средств, обладающих антигликирующей активностью
FR3068601B1 (fr) * 2017-07-05 2021-02-19 Eric Joseph Marie Fulgence Janin Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
MY203360A (en) * 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
WO2022152138A1 (zh) * 2021-01-15 2022-07-21 中国医药研究开发中心有限公司 稠和杂环类化合物及其制备方法和医药用途
CN118955413A (zh) * 2024-07-25 2024-11-15 宁夏恒康科技有限公司 一种盐酸伊美格列明的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287366A (en) * 1963-12-24 1966-11-22 American Cyanamid Co Novel 1, 2-dihydro-s-triazines
US3286366A (en) * 1964-10-26 1966-11-22 Seligman Monroe Apparatus for freeze drying products in small containers
JPS4856692A (is) * 1971-11-19 1973-08-09
JPS4864088A (is) * 1971-12-13 1973-09-05
JPS5414986A (en) * 1977-07-01 1979-02-03 Taiho Pharmaceutical Co Ltd Production of dihydrooss triazine derivative
US4246408A (en) * 1979-03-08 1981-01-20 Icn Pharmaceuticals Imidazo[1,2-a]-s-triazine
GR74944B (is) * 1980-07-02 1984-07-12 Merck & Co Inc
US4277602A (en) * 1980-07-02 1981-07-07 Merck & Co., Inc. 3-Amino-5-substituted-6-halo-N-(3,4-dihydro-6-substituted-1,3,5-truazin-2-yl)2-pyrazinecarboxamides
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
JPS6141915A (ja) 1984-08-03 1986-02-28 Omron Tateisi Electronics Co 測距装置
DD257010A1 (de) * 1987-01-13 1988-06-01 Berlin Chemie Veb Ergotrope mittel
DE3801113A1 (de) * 1987-07-23 1989-02-02 Bayer Ag Substituierte triazine
IT1244870B (it) * 1990-09-11 1994-09-12 Ministero Dall Uni E Della Ric Composti ammelinici
DE19641692A1 (de) * 1996-10-10 1998-04-23 Bayer Ag Substituierte 2,4-Diamino-1,3,5-triazine
DE69814151T2 (de) * 1997-12-12 2004-03-25 Abbott Laboratories, Abbott Park Triazin angiogenese-inhibitoren
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique

Also Published As

Publication number Publication date
NO20023532L (no) 2002-09-25
CZ303445B6 (cs) 2012-09-19
YU55602A (sh) 2005-03-15
CZ20022462A3 (cs) 2003-04-16
DE60121294T3 (de) 2010-09-23
BR0107815A (pt) 2002-10-29
EP1250328B1 (fr) 2006-07-05
BRPI0107815B1 (pt) 2017-08-29
BG106933A (en) 2003-07-31
CN1195743C (zh) 2005-04-06
EA200200790A1 (ru) 2003-02-27
US20080108591A1 (en) 2008-05-08
EE05003B1 (et) 2008-04-15
EA005378B1 (ru) 2005-02-24
DE60121294D1 (de) 2006-08-17
ES2267715T3 (es) 2007-03-16
DE60121294T2 (de) 2007-08-30
AR027293A1 (es) 2003-03-19
DK1250328T4 (da) 2010-06-28
NO20023532D0 (no) 2002-07-24
US7452883B2 (en) 2008-11-18
JP4926357B2 (ja) 2012-05-09
PL205345B1 (pl) 2010-04-30
PL357191A1 (en) 2004-07-26
ES2267715T5 (es) 2010-06-10
US20080108619A1 (en) 2008-05-08
JP2003520858A (ja) 2003-07-08
US20050165022A1 (en) 2005-07-28
SK9762002A3 (en) 2003-05-02
CA2397636C (fr) 2010-04-06
HK1050529A1 (en) 2003-06-27
US20030109530A1 (en) 2003-06-12
DK1250328T3 (da) 2006-10-30
HRP20020625A2 (en) 2003-10-31
SK287647B6 (sk) 2011-05-06
HUP0204087A3 (en) 2006-01-30
AU782307B2 (en) 2005-07-21
IL150530A0 (en) 2003-02-12
CY1105344T1 (el) 2010-03-03
HU230790B1 (en) 2018-05-02
KR100722438B1 (ko) 2007-05-29
ATE332294T1 (de) 2006-07-15
BRPI0107815B8 (pt) 2021-05-25
EP1250328B2 (fr) 2010-04-21
US7034021B2 (en) 2006-04-25
SI1250328T2 (sl) 2010-09-30
AU3560301A (en) 2001-08-07
EE200200414A (et) 2003-10-15
TNSN01012A1 (fr) 2005-11-10
SI1250328T1 (sl) 2006-10-31
AP2002002578A0 (en) 2002-09-30
US7767676B2 (en) 2010-08-03
MXPA02007232A (es) 2003-10-15
KR20020075395A (ko) 2002-10-04
HUP0204087A2 (hu) 2003-04-28
WO2001055122A1 (fr) 2001-08-02
CN1404472A (zh) 2003-03-19
PT1250328E (pt) 2006-10-31
FR2804113A1 (fr) 2001-07-27
FR2804113B1 (fr) 2004-06-18
CA2397636A1 (fr) 2001-08-02
EP1250328A1 (fr) 2002-10-23
OA12165A (fr) 2006-05-08
MA25650A1 (fr) 2002-12-31
ZA200205314B (en) 2005-07-27

Similar Documents

Publication Publication Date Title
IS6467A (is) Díhýdró-1,3,5-tríasín amínafleiður og notkun þeirra í meðferð
DK1233964T3 (da) Ny anvendelse og hidtil ukendte N-azabicycloamidderivater
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
DK1354888T3 (da) Glukopyranosyloxypyrazolderivater og anvendelse deraf i medikamenter
IS5696A (is) Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra
NO20021449L (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og deres anvendelse
NO20002486L (no) Sykliske aminderivater og deres anvendelse som legemidler
HUP0402025A3 (en) Novel bensophenone derivatives or salts thereof and their use
NO20031838D0 (no) Benzokazinonderivater, deres fremstilling og anvendelse
IS6420A (is) Setnar Fenýl-píperazín afleiður, framleiðsla þeirra og notkun
NO20001781D0 (no) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO986174D0 (no) Triazinderivater og anvendelse derav
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
DK1334106T3 (da) Imidazolderivater, fremstillingsmetoder deraf og anvendelse deraf
IL158254A0 (en) Indolinones, substituted in position 6, and their use as kinase inhibitors
IL166821A0 (en) Novel 1,4-diazabicycloalkane derivatives their preparation and use
NO20001934D0 (no) 3-Substituerte tetrahydropyridopyrimidinon-derivater, deres fremstilling og anvendelse
NO20024107L (no) Tienopyridin derivater, deres fremstilling og anvendelse
NO20001782L (no) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO20044090L (no) Substituert 3-fenyl-5-alkoksy-1,3,4-oksadiazol-24neJr, fremstilling derav og anvendelse i medikamenter
IS7259A (is) 3-Heteróarýl-3,5-díhýdró-4-oxó-4H-pýridasínó[4,5-b]indól-1-karboxamíð afleiður, framleiðsla þeirra og notkun þeirra við meðhöndlun
NO20022457D0 (no) Substituerte 1,2,3,4,5,6-heksahydro-2,6-metano-3-benzazociner og deres anvendelse som medikamenter
NO20022482L (no) 2-arylkinolinderivater, fremgangsmåte og terapeutisk anvendelse derav
NO20023687D0 (no) 1,3,4-oksadiazolderivater og fremgangsmåte for fremstilling derav
HRP20020971A2 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-inhibitors